WO2008119771A3 - Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors - Google Patents

Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors Download PDF

Info

Publication number
WO2008119771A3
WO2008119771A3 PCT/EP2008/053763 EP2008053763W WO2008119771A3 WO 2008119771 A3 WO2008119771 A3 WO 2008119771A3 EP 2008053763 W EP2008053763 W EP 2008053763W WO 2008119771 A3 WO2008119771 A3 WO 2008119771A3
Authority
WO
WIPO (PCT)
Prior art keywords
quinoline
carboxylic acid
acid derivatives
tyrosine kinase
kinase inhibitors
Prior art date
Application number
PCT/EP2008/053763
Other languages
French (fr)
Other versions
WO2008119771A2 (en
Inventor
Jacob Westman
Johan Wannberg
Natalia Nekhotiaeva
Ulrika Baeckman
Original Assignee
Clanotech Ab
Jacob Westman
Johan Wannberg
Natalia Nekhotiaeva
Ulrika Baeckman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clanotech Ab, Jacob Westman, Johan Wannberg, Natalia Nekhotiaeva, Ulrika Baeckman filed Critical Clanotech Ab
Publication of WO2008119771A2 publication Critical patent/WO2008119771A2/en
Publication of WO2008119771A3 publication Critical patent/WO2008119771A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A quinoline-3-carboxyderivative of formula (I), a method for preparing it and use ofthe derivativein therapy, in particular for the treatment and prevention of cell proliferative disorders or cell differentiation disorders.
PCT/EP2008/053763 2007-03-30 2008-03-28 Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors WO2008119771A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92081207P 2007-03-30 2007-03-30
SE0700803 2007-03-30
SE0700803-0 2007-03-30
US60/920,812 2007-03-30

Publications (2)

Publication Number Publication Date
WO2008119771A2 WO2008119771A2 (en) 2008-10-09
WO2008119771A3 true WO2008119771A3 (en) 2008-12-04

Family

ID=39731042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/053763 WO2008119771A2 (en) 2007-03-30 2008-03-28 Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors

Country Status (1)

Country Link
WO (1) WO2008119771A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2220047E (en) 2007-11-15 2015-07-30 Clanotech Ab Quinoline derivatives, pharmaceutical compositions comprising them, and use thereof
JP2012522750A (en) 2009-04-01 2012-09-27 ビーエーエスエフ ソシエタス・ヨーロピア Isoxazoline compounds for combating invertebrate pests
AU2010251134A1 (en) * 2009-05-20 2011-12-08 Clanotech Ab Substituted quinolines for use as VEGF inhibitors
US9604963B2 (en) 2011-03-04 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
TWI547494B (en) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 Amino quinazolines as kinase inhibitors
WO2013102936A1 (en) 2012-01-03 2013-07-11 Council Of Scientific & Industrial Research N-(3-((diethylamino) methyl)-4-hydroxyphenyl)-n-(quinolin-4-yl) sulfonamides for the treatment of tuberculosis and process of preparation thereof
JP6069356B2 (en) * 2012-01-05 2017-02-01 クラノテク・アクチボラグ Quinoline compounds that are anti-angiogenic integrin α5β1 inhibitors for use in the treatment of fibrosis or fibrosis related diseases
AR092530A1 (en) 2012-09-13 2015-04-22 Glaxosmithkline Llc AMINO-QUINOLINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOUND FOR THE PREPARATION OF A MEDICINAL PRODUCT
AR092529A1 (en) 2012-09-13 2015-04-22 Glaxosmithkline Llc AMINOQUINAZOLINE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOSITE FOR THE PREPARATION OF A MEDICINAL PRODUCT
BR112015019624A2 (en) 2013-02-21 2017-07-18 Glaxosmithkline Ip Dev Ltd quinazolines as kinase inhibitors
WO2019084271A1 (en) * 2017-10-25 2019-05-02 Children's Medical Center Corporation Papd5 inhibitors and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
WO2004069250A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
WO2007139496A1 (en) * 2006-05-30 2007-12-06 Clanotech Ab Quinoline derivatives acting as tyrosine kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
WO2004069250A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
WO2007139496A1 (en) * 2006-05-30 2007-12-06 Clanotech Ab Quinoline derivatives acting as tyrosine kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM ET AL: "Putative therapeutic agents for the learning and memory deficits of people with Down syndrome", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 16, no. 14, 15 July 2006 (2006-07-15), pages 3772 - 3776, XP005477331, ISSN: 0960-894X *
SAPELKIN V M ET AL: "Search for protein kinase CK2 inhibitors among 3-carboxy-4-aminoquinoline derivatives", UKRAINICA BIOORGANICA ACTA, BIOLOHII I HENETYKY, vol. 2, no. 1, 1 January 2005 (2005-01-01), pages 28 - 32, XP003018391, ISSN: 1814-9758 *

Also Published As

Publication number Publication date
WO2008119771A2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
WO2008119771A3 (en) Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2009011850A3 (en) Novel therapeutic compounds
WO2010038086A8 (en) P38 map kinase inhibitors
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2007129226A3 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
WO2007111904A3 (en) C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2009117482A8 (en) Mtor inhibitor salt forms
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2007095188A3 (en) Dihydrodiazepines useful as inhibitors of protein kinases
EP1945631B8 (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
SI2125822T1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2009108383A3 (en) Substituted xanthine derivatives
WO2008112651A3 (en) Aminopyrimidines useful as inhibitors of protein kinases
MX2009008253A (en) Kinase inhibitors.
WO2008137619A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
WO2008147626A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
MX2009012595A (en) Spiroindolinone derivatives.
WO2007087283A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
MX2009009117A (en) Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors.
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
WO2007139816A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08735585

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08735585

Country of ref document: EP

Kind code of ref document: A2